Impact of tumor-treating fields on the survival of Japanese patients with newly diagnosed glioblastoma: A multicenter, retrospective cohort study

被引：0

作者：

Kanamori, Masayuki ^{[1
]}

Tsuzuki, Shunsuke ^{[2
]}

Shibahara, Ichiyo ^{[3
]}

Saito, Kuniaki ^{[4
]}

Shimoda, Yoshiteru ^{[1
]}

Tanaka, Kazuhiro ^{[5
]}

Yamaguchi, Shigeru ^{[6
]}

Natsumeda, Manabu ^{[7
]}

Matsutani, Tomoo ^{[8
]}

Hanihara, Mitsuto ^{[9
]}

Nakada, Mitsutoshi ^{[10
]}

Kuroda, Jun-Ichiro ^{[11
]}

Matsuda, Masahide ^{[12
]}

Yoshimoto, Koji ^{[13
]}

Yonezawa, Ushio ^{[14
]}

Sonoda, Yukihiko ^{[15
]}

Takano, Koji ^{[16
]}

Yonezawa, Hajime ^{[17
]}

Otani, Yoshihiro ^{[18
]}

Nakahara, Yukiko ^{[19
]}

Uchida, Masashi ^{[20
]}

Nonaka, Masahiro ^{[21
]}

Mineharu, Yohei ^{[22
]}

Kitamura, Yohei ^{[23
]}

Yamashita, Shinji ^{[24
]}

Yamauchi, Takahiro

Miyake, Yohei ^{[26
]}

Deguchi, Shoichi ^{[27
]}

Beppu, Takaaki ^{[28
]}

Tamura, Kaoru ^{[29
]}

Koizumi, Shinichiro ^{[30
]}

Hirose, Yuichi ^{[31
]}

Asano, Kenichiro ^{[32
]}

Hiruta, Ryo ^{[33
]}

Kinoshita, Manabu ^{[34
]}

Miyake, Keisuke ^{[35
]}

Nakayama, Noriyuki ^{[36
]}

Inoue, Akihiro ^{[37
]}

Ono, Takahiro ^{[38
]}

Sasaki, Takahiro ^{[39
]}

Akiyama, Yukinori ^{[40
]}

Fukami, Shinjiro ^{[41
]}

Yoshino, Atsuo ^{[42
]}

Kawanishi, Yu ^{[43
]}

Asanome, Taku ^{[44
]}

Yamaguchi, Takuhiro ^{[25
,45
]}

Takahashi, Masamichi ^{[46
]}

Yamasaki, Fumiyuki ^{[14
]}

Arakawa, Yoshiki ^{[22
]}

Narita, Yoshitaka ^{[46
]}

机构：

[1] Tohoku Univ, Grad Sch Med, Dept Neurosurg, 1-1 Seiryo Cho,Aoba Ku, Sendai, Japan

[2] Tokyo Womens Med Univ, Dept Neurosurg, Tokyo, Japan

[3] Kitasato Univ, Sch Med, Dept Neurosurg, Sagamihara, Japan

[4] Kyorin Univ Facil Med, Dept Neurosurg, Tokyo, Japan

[5] Kobe Univ, Grad Sch Med, Dept Neurosurg, Kobe, Japan

[6] Hokkaido Univ, Fac Med, Dept Neurosurg, Sapporo, Japan

[7] Niigata Univ, Brain Res Inst, Dept Neurosurg, Niigata, Japan

[8] Chiba Univ, Grad Sch Med, Dept Neurol Surg, Chiba, Japan

[9] Univ Yamanashi, Dept Neurosurg, Yamanashi, Japan

[10] Kanazawa Univ, Dept Neurosurg, Kanazawa, Japan

[11] Kumamoto Univ, Fac Life Sci, Dept Neurosurg, Kumamoto, Japan

[12] Univ Tsukuba, Inst Med, Dept Neurosurg, Tsukuba, Japan

[13] Kyushu Univ, Grad Sch Med Sci, Dept Neurosurg, Fukuoka, Japan

[14] Hiroshima Univ, Grad Sch Biomed & Hlth Sci, Dept Neurosurg, Hiroshima, Japan

[15] Yamagata Univ, Fac Med, Dept Neurosurg, Yamagata, Japan

[16] Osaka Int Canc Inst, Dept Neurosurg, Osaka, Japan

[17] Kagoshima Univ, Grad Sch Med & Dent Sci, Dept Neurosurg, Kagoshima, Japan

[18] Okayama Univ, Grad Sch Med Dent & Pharmaceut Sci, Dept Neurol Surg, Okayama, Japan

[19] Saga Univ, Fac Med, Dept Neurosurg, Saga, Japan

[20] St Marianna Univ, Sch Med, Dept Neurosurg, Kawasaki, Kanagawa, Japan

[21] Kansai Med Univ, Dept Neurosurg, Hirakara, Japan

[22] Kyoto Univ, Grad Sch Med, Dept Neurosurg, Kyoto, Japan

[23] Keio Univ, Sch Med, Dept Neurosurg, Tokyo, Japan

[24] Univ Miyazaki, Fac Med, Dept Clin Neurosci, Div Neurosurg, Miyazaki, Japan

[25] Univ Fukui, Fac Med Sci, Dept Neurosurg, Div Med, Fukui, Japan

[26] Yokohama City Univ, Grad Sch Med, Dept Neurosurg, Yokohama, Japan

[27] Shizuoka Canc Ctr, Div Neurosurg, Nagaizumi, Japan

[28] Iwate Med Univ, Dept Neurosurg, Shiwa, Japan

[29] Tokyo Med & Dent Univ, Dept Neurosurg, Tokyo, Japan

[30] Hamamatsu Univ, Sch Med, Dept Neurosurg, Hamamatsu, Japan

[31] Fujita Hlth Univ, Dept Neurosurg, Toyoake, Japan

[32] Hirosaki Univ, Grad Sch Med, Dept Neurosurg, Hirosaki, Japan

[33] Fukushima Med Univ, Dept Neurosurg, Fukushima, Japan

[34] Asahikawa Med Univ, Dept Neurosurg, Asahikawa, Hokkaido, Japan

[35] Kagawa Univ, Fac Med, Dept Neurol Surg, Kagawa, Japan

[36] Gifu Univ, Grad Sch Med, Dept Neurosurg, Gifu, Japan

[37] Ehime Univ, Sch Med, Dept Neurosurg, Toon, Japan

[38] Akita Univ, Grad Sch Med, Dept Neurosurg, Akita, Japan

[39] Wakayama Med Univ, Sch Med, Dept Neurol Surg, Wakayama, Japan

[40] Sapporo Med Univ, Dept Neurosurg, Sapporo, Japan

[41] Tokyo Med Univ, Dept Neurosurg, Tokyo, Japan

[42] Nihon Univ, Sch Med, Dept Neurol Surg, Tokyo, Japan

[43] Kochi Univ, Kochi Med Sch, Dept Neurosurg, Kochi, Japan

[44] Nakamura Mem Hosp, Brain Tumor Ctr, Dept Neurosurg, Sapporo, Japan

[45] Tohoku Univ, Grad Sch Med, Div Biostat, Sendai, Japan

[46] Natl Canc Ctr, Dept Neurosurg & Neurooncol, Tokyo, Japan

来源：

NEURO-ONCOLOGY ADVANCES | 2024年 / 6卷 / 01期

关键词：

Asian population; determinant of use; glioblastoma; survival; tumor-treating fields; PHASE-II; TEMOZOLOMIDE; CHEMOTHERAPY; RESECTION; EFFICACY; CRITERIA; EXTENT; TRIAL; WAFER;

D O I：

10.1093/noajnl/vdae176

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Background. The EF-14 clinical trial demonstrated the safety and efficacy of tumor-treating fields (TTFields) for newly diagnosed glioblastoma. This study aimed to clarify the current status, safety, and efficacy of TTFields in Japanese patients who meet the EF-14 inclusion criteria. Methods. This was a multicenter retrospective cohort study. Background, treatment, and outcome data of patients who satisfied the inclusion criteria of the EF-14 trial were collected from 45 institutions across Japan. The rate, determinants, and current status of TTField use, including its safety and efficacy in terms of progression and survival, were retrospectively investigated. This study was conducted in accordance with the STROBE checklist. Results. Among the 607 patients enrolled, 70 were excluded due to progressive disease during radiation and temozolomide therapy, age > 80 years old, and Karnofsky Performance Status score of <70. Among the remaining 537 patients, 210 (39%) underwent TTField treatment. Multivariate analysis revealed younger age and spouse as a caregiver as significant factors for TTField use. The compliance rate of TTField use exceeded 75% in 60% of patients, with a median TTField usage duration of 11 months. Skin disorders requiring medical treatment occurred in 56% of patients. Multivariate Cox proportional hazards analysis in the whole series and propensity score-matched analysis revealed that TTField use was not a prognostic factor for progression-free survival (PFS) or overall survival (OS). Conclusions. TTField use did not have a substantial effect on either PFS or OS in Japanese patients with glioblastoma, despite compliance rates comparable to those observed in the EF-14.

引用

页数：11

共 50 条

[31] Influence of Treatment With Tumor-Treating Fields on Health-Related Quality of Life of Patients With Newly Diagnosed Glioblastoma A Secondary Analysis of a Randomized Clinical Trial
Taphoorn, Martin J. B.
Dirven, Linda
Kanner, Andrew A.
Lavy-Shahaf, Gitit
Weinberg, Uri
Taillibert, Sophie
Toms, Steven A.
Honnorat, Jerome
Chen, Thomas C.
Sroubek, Jan
David, Carlos
Idbaih, Ahmed
Easaw, Jacob C.
Kim, Chae-Yong
Bruna, Jordi
Hottinger, Andreas F.
Kew, Yvonne
Roth, Patrick
Desai, Rajiv
Villano, John L.
Kirson, Eilon D.
Ram, Zvi
Stupp, Roger
JAMA ONCOLOGY, 2018, 4 (04) : 495 - 504
[32] Impact of Body Mass Index on Survival Outcome in Patients with Newly Diagnosed Glioblastoma: A Retrospective Single-Center Study
Cha, Jun-Yong
Park, Jae-Sung
Hong, Yong-Kil
Jeun, Sin-Soo
Ahn, Stephen
INTEGRATIVE CANCER THERAPIES, 2021, 20
[33] Tumour Treating Fields (TTFields) in combination with lomustine and temozolomide in patients with newly diagnosed glioblastoma
Lazaros Lazaridis
Niklas Schäfer
Sarah Teuber-Hanselmann
Tobias Blau
Teresa Schmidt
Christoph Oster
Johannes Weller
Theophilos Tzaridis
Daniela Pierscianek
Kathy Keyvani
Christoph Kleinschnitz
Martin Stuschke
Björn Scheffler
Cornelius Deuschl
Ulrich Sure
Ulrich Herrlinger
Sied Kebir
Martin Glas
Journal of Cancer Research and Clinical Oncology, 2020, 146 : 787 - 792
[34] Tumour Treating Fields (TTFields) in combination with lomustine and temozolomide in patients with newly diagnosed glioblastoma
Lazaridis, Lazaros
Schaefer, Niklas
Teuber-Hanselmann, Sarah
Blau, Tobias
Schmidt, Teresa
Oster, Christoph
Weller, Johannes
Tzaridis, Theophilos
Pierscianek, Daniela
Keyvani, Kathy
Kleinschnitz, Christoph
Stuschke, Martin
Scheffler, Bjoern
Deuschl, Cornelius
Sure, Ulrich
Herrlinger, Ulrich
Kebir, Sied
Glas, Martin
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2020, 146 (03) : 787 - 792
[35] Real-world cost- effectiveness analysis: Tumor Treating Fields for newly diagnosed glioblastoma in China
Xiang, Yuliang
Chen, Yingyao
Xu, Zian
Zhou, Shanyan
Qin, Zhiyong
Chen, Lingchao
Xiao, Dunming
Liu, Shimeng
JOURNAL OF NEURO-ONCOLOGY, 2024, 168 (02) : 259 - 267
[36] Long-term survival, patterns of progression, and patterns of use for patients with newly diagnosed glioblastoma treated with or without Tumor Treating Fields (TTFields) in a real-world setting
Riegel, Devon C.
Bureau, Britta L.
Conlon, Patrick
Chavez, Gordon
Connelly, Jennifer M.
JOURNAL OF NEURO-ONCOLOGY, 2025, : 49 - 57
[37] Concurrent chemoradiation and Tumor Treating Fields (TTFields, 200 kHz) for patients with newly diagnosed glioblastoma: patterns of progression in a single institution pilot study
Ali, Ayesha S.
Lombardo, Joseph
Niazi, Muneeb Z.
Miller, Ryan C.
Alnahhas, Iyad
Martinez, Nina L.
Andrews, David W.
Judy, Kevin D.
Shi, Wenyin
JOURNAL OF NEURO-ONCOLOGY, 2022, 160 (02) : 345 - 350
[38] A nomogram for individualized prediction of overall survival in patients with newly diagnosed glioblastoma: a real-world retrospective cohort study
Nijiati Kudulaiti
Zhirui Zhou
Chen Luo
Jie Zhang
Fengping Zhu
Jinsong Wu
BMC Surgery, 21
[39] Critical review of the addition of tumor treating fields (TTFields) to the existing standard of care for newly diagnosed glioblastoma patients
Mehta, M.
Wen, P.
Nishikawa, R.
Reardon, D.
Peters, K.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2017, 111 : 60 - 65
[40] Impact of Age and Gender on Survival of Glioblastoma Multiforme Patients: A Multicenter Retrospective Study
Reihanian, Zoheir
Abbaspour, Elahe
Zaresharifi, Nooshin
Karimzadhagh, Sahand
Mahmoudalinejad, Maral
Sourati, Ainaz
Farzin, Mohaya
Eslamikenarsari, Habib
CANCER REPORTS, 2024, 7 (11)

← 1 2 3 4 5 →